Document is current
Any future updates will be listed below
-
Authors
Kameda, Takuro
Utsunomiya, Atae
Otsuka, Nobuaki
Kubuki, Yoko
Uchida, Taisuke
Shide, Kotaro
Kamiunten, Ayako
Nakano, Nobuaki
Tokunaga, Masahito
Miyazono, Takayoshi
Ito, Yoshikiyo
Yonekura, Kentaro
Kawakita, Toshiro
Akizuki, Keiichi
Tahira, Yuki
Karasawa, Masayoshi
Hidaka, Tomonori
Konagata, Ayaka
Taniguchi, Norifumi
Nagatomo, Yuma
Kogo, Fumiko
Shimizu, Koichiro
Ueno, Hiroaki
Ishizaki, Junzo
Takahashi, Naoya
Ikei, Yoshihiko
Hidaka, Michihiro
Yamaguchi, Hideki
Shimoda, Kazuya
-
Funding
Funding for this research was provided by:
University of Miyazaki Hospital (R4)
Japan Agency for Medical Research and Development (21ck0106538h0002)
- License Information
-
More Information
Article History
Received: 28 August 2023
Accepted: 9 January 2024
First Online: 17 January 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of the Faculty of Medicine, University of Miyazaki, and other participating institutes (O-1061). Written informed consent was obtained from all study participants.
: Not Applicable.
: K. Shimoda received consulting fees from Novartis Pharma, Takeda Pharmaceutical, and Bristol-Myers, all outside the submitted work, and received research grants from Perseus Proteomics, Pharma Essentia Japan KK, AbbVie GK, Astellas Pharma, MSD, Chugai Pharmaceutical, Kyowa Kirin, Pfizer, Novartis Pharma, Otsuka Pharmaceutical, and Asahi Kasei Medical, all outside the submitted work. A. Utsunomiya has received honoraria from Kyowa Kirin, Daiichi Sankyo, Bristol-Myers Squibb, and Meiji Seika Pharma and consulting fees from JIMRO and Otsuka Medical Devices, all outside the submitted work. M. Hidaka received honoraria from Chugai Pharm. And Huya, Japan. The authors declare no conflicts of interest.
